Mary Katherine Cheeley
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mary Katherine Cheeley has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Connor Lockridge
Grady Health System, Atlanta, USA
1 shared publication - Katarina Clegg
Geisinger Commonwealth School of Medicine, Scranton, USA
1 shared publication - Laney K. Jones
Geisinger
1 shared publication - Laurie Cavendish
Grady Health System
1 shared publication - Tyler J. Schubert
Department of Genomic Health, Geisinger, Danville, PA, USA (Dr Schubert); Geisinger Commonwealth School of Medicine, Scranton, PA, USA (Dr Schubert)
1 shared publication
Latest Publications
- 24 May 2024
- Published by Springer Nature
- p. 67-81
Pharmaceutical Development and Approval in the United States of Agents to Influence Cardiovascular Health
- 24 May 2024
- Published by Springer Nature
- p. 67-81
Pharmaceutical Development and Approval in the United States of Agents to Influence Cardiovascular Health
- Open Access
- 6 July 2023
- Published by Springer Nature in Current Atherosclerosis Reports
- Vol. 25 (8) , 517-526
Statin Intolerance: an Overview of US and International Guidance
Purpose of Review: To review recent international and domestic definitions, considerations, and treatment algorithms for statin intolerance, and specifically, statin-associated muscle symptoms (SAMS). Recent Findings: Multiple organizations around the world have produced guidance documents to aid clinicians on managing statin intolerance. A common theme resides among all the guidance documents that most patients can tolerate statins. For those patients who cannot, healthcare teams need to evaluate, rechallenge, educate, and ensure adequate reduction of atherogenic lipoproteins. Summary: Statin therapy remains the cornerstone of lipid-lowering therapies to reduce atherosclerotic cardiovascular disease (ASCVD) and reduce mortality and morbidity. The common theme throughout all these guidance documents is the importance of statin therapy to reduce ASCVD and continual adherence to treatment. Because adverse events occur and inhibit patients from achieving adequate lowering of their atherogenic lipoproteins, trial and rechallenge of statin therapy, as well as addition of non-statin therapies, especially in high-risk patients, is also undisputed. The main differences stem from laboratory monitoring and the classification of the severity of the adverse effect. Future research should focus on consistently diagnosing SAMS so that these patients can be easily identified in the electronic health records.
- 6 July 2023
- Published by Springer Nature in Current Atherosclerosis Reports
- Vol. 25 (8) , 517-526
Open AccessStatin Intolerance: an Overview of US and International Guidance
Purpose of Review: To review recent international and domestic definitions, considerations, and treatment algorithms for statin intolerance, and specifically, statin-associated muscle symptoms (SAMS). Recent Findings: Multiple organizations around the world have produced guidance documents to aid clinicians on managing statin intolerance. A common theme resides among all the guidance documents that most patients can tolerate statins. For those patients who cannot, healthcare teams need to evaluate, rechallenge, educate, and ensure adequate reduction of atherogenic lipoproteins. Summary: Statin therapy remains the cornerstone of lipid-lowering therapies to reduce atherosclerotic cardiovascular disease (ASCVD) and reduce mortality and morbidity. The common theme throughout all these guidance documents is the importance of statin therapy to reduce ASCVD and continual adherence to treatment. Because adverse events occur and inhibit patients from achieving adequate lowering of their atherogenic lipoproteins, trial and rechallenge of statin therapy, as well as addition of non-statin therapies, especially in high-risk patients, is also undisputed. The main differences stem from laboratory monitoring and the classification of the severity of the adverse effect. Future research should focus on consistently diagnosing SAMS so that these patients can be easily identified in the electronic health records.